Endologix Acquires Pounce Thrombectomy System from Surmodics: What the Deal Means for Peripheral Vascular Intervention

The Deal at a Glance

On May 19, 2026, Endologix LLC announced the acquisition of the Pounce Thrombectomy System from Surmodics, Inc. The transaction closed on May 18, 2026. Financial terms were not disclosed.

While the undisclosed financial terms make direct valuation comparisons difficult, the deal is best understood in context: Surmodics's entire company was acquired by private equity firm GTCR for $627 million just months earlier. The Pounce divestiture represents a carve-out of Surmodics's device business to allow the company to focus on its core hydrophilic coatings and drug-coated balloon franchises under GTCR ownership.

The Pounce Thrombectomy System

Technology Overview

The Pounce Thrombectomy System is an FDA-cleared, fully mechanical platform for the non-surgical removal of thrombi and emboli from peripheral arteries. It is designed as a "grab-and-go" solution that does not rely on capital equipment, thrombolytic drugs, or aspiration pumps.

Each Pounce system consists of three components:

1. Delivery catheter — advances the system to the treatment site through a guide sheath
2. Basket wire — deploys two self-expanding nitinol baskets that capture and entrap the clot
3. Funnel catheter — a nitinol collection funnel that receives the baskets and clot for withdrawal through the guide sheath

The procedure workflow:

1. The delivery catheter is advanced past the thrombus under fluoroscopic guidance
2. The first nitinol basket is deployed distal to the clot
3. The second basket is deployed proximal to the clot
4. Both baskets are retracted into the nitinol collection funnel, capturing the thrombus
5. The entire assembly is withdrawn through the guide sheath, removing the clot from the body

Platform Configurations

The Pounce platform includes three commercially available configurations designed to treat peripheral arterial vessels of different sizes:

This range of configurations allows vascular interventionalists to select the appropriate device based on vessel anatomy and clot burden without switching to a different technology platform.

Regulatory History

Clinical Differentiation

Pounce differentiates itself from other thrombectomy approaches in several ways:

Mechanical vs. Pharmacological: Unlike catheter-directed thrombolysis (CDT), which dissolves clots using lytic drugs over hours or days, Pounce removes clots mechanically in a single procedure. This eliminates the bleeding risk associated with thrombolytics and the need for ICU monitoring during extended infusion.

No Capital Equipment Required: Unlike aspiration thrombectomy systems (which require pump consoles) or mechanical rotational devices (which require drive units), Pounce operates entirely through manual catheter mechanics. This reduces per-procedure cost and eliminates the need for hospitals to invest in dedicated thrombectomy consoles.

Dual-Basket Capture: The two-basket design provides more reliable clot engagement compared to single-element devices, particularly for elongated or fragmented thrombi in peripheral arteries.

The Players

Endologix LLC

Endologix is a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease. The company is headquartered in Santa Rosa, California (formerly Irvine), and is wholly owned by Deerfield Management, a healthcare-focused investment firm.

Existing Commercial Portfolio:

Endologix's existing portfolio addresses aortic aneurysm repair and peripheral arterial disease (PAD). Adding Pounce extends the company's reach into the thrombectomy segment — specifically, the treatment of acute thrombotic and embolic occlusions in peripheral arteries.

CEO John Liddicoat, MD, emphasized that Pounce "serves the same physicians and patients we already work with every day," making this a customer-base consolidation deal rather than a market expansion play. Vascular interventionalists who use Endologix's DETOUR system for chronic femoropopliteal occlusions now have access to a mechanical thrombectomy option from the same company for acute clot presentations.

Dr. Venkatesh Ramaiah, Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute in Scottsdale, Arizona, provided clinical context: "I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense. The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix's portfolio of vascular technologies for the treatment of peripheral arterial disease."

Surmodics, Inc.

Surmodics, Inc. (Eden Prairie, Minnesota) is a medical device and in vitro diagnostic technology company that has undergone significant transformation over the past year.

The GTCR Acquisition Saga:

The FTC's challenge centered on hydrophilic coatings — friction-reducing coatings applied to catheters, guidewires, and other interventional devices. The agency argued that combining Surmodics (the largest outsourced coating supplier, ~12% global share) with Biocoat (second largest, ~8.5% share) would create a company controlling over 50% of the U.S. outsourced hydrophilic coatings market.

The court ultimately sided with GTCR, finding that the proposed divestiture to Integer Holdings was sufficient to preserve competition. This was the first litigated merger challenge under the second Trump administration and a significant defeat for the FTC's antitrust enforcement strategy.

Post-Acquisition Strategy:

Under GTCR ownership, Surmodics is focused on its core franchises:

• Hydrophilic coatings (Serene, Preside) for medical device manufacturers
• Drug-coated balloons (Surveil) for peripheral arterial disease treatment
• In vitro diagnostic reagents and coatings

Selling the Pounce thrombectomy system to Endologix allows Surmodics to fully concentrate on coatings and drug-device combination products — the businesses that aligned with GTCR's original investment thesis. The Pounce device business, while innovative, was tangential to Surmodics's coatings-centric identity.

The PAD and Thrombectomy Market

Peripheral Arterial Disease: Scale of the Problem

Peripheral arterial disease (PAD) affects more than 12 million Americans and an estimated 200 million individuals globally, according to the American College of Cardiology. Risk factors include diabetes, hypertension, smoking, obesity, and aging — all of which are increasing in prevalence.

PAD ranges from asymptomatic to critical limb ischemia (CLI), the most severe form, which carries a high risk of amputation and mortality. Between these extremes, patients may develop acute thrombotic or embolic occlusions in peripheral arteries — the target indication for the Pounce system.

The Thrombectomy Device Market

The global atherectomy and thrombectomy devices market is experiencing steady growth, with North America accounting for approximately 47% of the market. Key growth drivers include:

• Rising PAD prevalence driven by aging populations and increasing diabetes/obesity rates
• Shift toward minimally invasive endovascular procedures over open surgical bypass
• Technological innovation in mechanical thrombectomy, aspiration, and pharmacomechanical approaches
• Expanding indications for thrombectomy in peripheral, coronary, and neurovascular applications

The peripheral vascular devices market (which includes stents, balloons, atherectomy, thrombectomy, and accessories) was valued at approximately $10.02 billion in 2026 and is projected to reach $13.22 billion by 2031 at a CAGR of 5.7%, according to MarketsandMarkets. The atherectomy and thrombectomy devices market specifically was valued at approximately $4.2 billion in 2026, projected to reach $6.9 billion by 2033 at 5.3% CAGR (Persistence Market Research). North America accounts for approximately 47.3% of the global thrombectomy market.

Competitive Landscape for Mechanical Thrombectomy

The Pounce system's niche is fully mechanical, capital-equipment-free clot removal in peripheral arteries. This positions it differently from aspiration systems (which require pumps) and pharmacomechanical systems (which require lytic drugs and ICU monitoring).

Strategic Rationale

For Endologix

1. Portfolio Complementarity

Endologix's existing products treat chronic vascular conditions (aortic aneurysms, chronic femoropopliteal occlusions). Pounce adds an acute intervention capability — mechanical clot removal for acute thrombotic and embolic events. This creates a more complete product offering for vascular interventionalists.

2. Same Physician Customer Base

Both Endologix and Pounce target vascular interventionalists — the same physicians who perform endovascular procedures in catheterization labs and interventional suites. Adding Pounce deepens Endologix's relationship with these physicians without requiring a new sales channel or customer acquisition effort.

3. PAD Market Growth

The peripheral arterial disease market is growing as populations age and diabetes/obesity prevalence increases. A comprehensive PAD portfolio — spanning chronic occlusion treatment (DETOUR), aneurysm repair (AFX2, ALTO), and acute clot removal (Pounce) — positions Endologix to capture a larger share of vascular intervention procedures.

4. Deerfield's Platform Strategy

Endologix's owner, Deerfield Management, has been building a vascular intervention platform. The Pounce acquisition is consistent with a private equity strategy of acquiring complementary assets to build a more valuable platform company — potentially preparing Endologix for a future exit (IPO or strategic sale).

For Surmodics (and GTCR)

1. Focus on Core Coatings Business

The Pounce device business was tangential to Surmodics's core competency in surface modification technologies (hydrophilic coatings, drug-coated balloons). Divesting it allows the company to concentrate resources on its coatings franchise and the Surveil drug-coated balloon, which represents a significant commercial opportunity in PAD treatment.

2. Simplified Post-Merger Integration

Following GTCR's acquisition of Surmodics, integrating the coating businesses (Surmodics + Biocoat) while managing a standalone device franchise added complexity. The Pounce divestiture simplifies the integration.

3. Eliminating Competitive Conflicts

Surmodics's drug-coated balloon (Surveil) competes in the same PAD treatment space as some potential Pounce customers. Owning both a thrombectomy device and a drug-coated balloon could create channel conflict with other device manufacturers who are Surmodics coating customers. Divesting Pounce removes this conflict.

FTC Antitrust Context: The GTCR-Surmodics Precedent

The Pounce divestiture cannot be understood without the FTC's challenge to GTCR's $627 million acquisition of Surmodics. That case was the first litigated merger challenge under the second Trump administration and produced several important precedents for medtech M&A:

Key Takeaways from the FTC Case

1. Divestiture as a Fix Can Work

GTCR proposed divesting certain Biocoat coating assets to Integer Holdings as a remedy for competitive concerns. The FTC rejected this fix, arguing it was insufficient. However, the court agreed with GTCR that the divestiture preserved competition — marking a victory for the "litigate the fix" defense strategy.

2. Private Equity Deals Remain Under Scrutiny

Despite the loss, the FTC's challenge confirms that private equity roll-up strategies in medtech — particularly those combining direct competitors in niche markets — will continue to face antitrust scrutiny.

3. Niche Market Definition Matters

The case turned on how the market was defined: "outsourced hydrophilic coatings for medical devices" is a narrow segment where two players combining would control over 50%. The FTC's economic expert calculated a post-merger HHI exceeding 3,500 with a change of over 1,000 — levels that presumptively violate antitrust guidelines.

4. Implications for Future MedTech M&A

The court's acceptance of a partial divestiture remedy (rather than requiring a full business carve-out) provides a roadmap for future medtech merger challenges. Companies pursuing acquisitions in concentrated market segments should consider pre-emptive divestiture strategies to address competitive concerns.

Broader Cardiovascular M&A Context

The Endologix-Pounce deal is part of a remarkable wave of cardiovascular medtech M&A in 2025-2026:

The cardiovascular segment is the clear center of gravity in medtech M&A. ZS's 2026 medtech trends analysis notes that cardiovascular "remains the clear center of gravity" for dealmaking, driven by "strong and reliable reimbursement" and high growth potential in interventional procedures.

Within this broader trend, the thrombectomy segment has been particularly active. Boston Scientific's $14.5 billion acquisition of Penumbra — announced in January 2026 — was a bet on the growth of mechanical thrombectomy across neurovascular, peripheral, and coronary applications. The Endologix-Pounce deal, while vastly smaller, targets the same therapeutic area.

Implications for Medical Device Professionals

For Vascular Interventionalists

The Pounce system's transition from Surmodics to Endologix should be operationally seamless during the transition period — the device will continue to be marketed under its existing FDA clearance. However, physicians should monitor:

• Any changes to the Pounce sales and support team during the integration
• Potential bundling or pricing changes as Endologix incorporates Pounce into its vascular portfolio
• Whether Endologix invests in next-generation Pounce configurations or expanded indications

For Regulatory Affairs Teams

The deal illustrates an important regulatory consideration: FDA-cleared devices can be transferred between owners without new 510(k) submissions, provided the device design, intended use, and manufacturing processes remain unchanged. However, any post-acquisition modifications to Pounce would trigger new regulatory submissions from Endologix as the new legal manufacturer.

For MedTech BD Teams

The Pounce divestiture demonstrates that product carve-outs are a viable pathway for companies seeking to sharpen their focus after a major acquisition. For BD teams, this creates opportunities to acquire complementary assets from companies going through post-merger portfolio rationalization — particularly in the current environment of active cardiovascular M&A.

Key Takeaways

• Endologix acquired the Pounce mechanical thrombectomy system from Surmodics, adding a capital-equipment-free, dual-basket clot removal platform to its peripheral vascular portfolio
• The deal follows GTCR's $627M acquisition of Surmodics, which survived an FTC antitrust challenge; selling Pounce allows Surmodics to focus on its core coatings and drug-coated balloon franchises
• Pounce serves the same vascular interventionalist customer base as Endologix's existing DETOUR, ALTO, and AFX2 platforms, deepening customer relationships without requiring new distribution
• The peripheral vascular devices market (~$9.85B in 2024, growing to ~$15.5B by 2032) continues to attract M&A investment, with thrombectomy being a particularly active segment
• The deal is part of the broader cardiovascular M&A consolidation wave of 2025-2026, which includes Boston Scientific-Penumbra ($14.5B), multiple Medtronic acquisitions, and J&J's Atraverse purchase
• The FTC's failed challenge to the GTCR-Surmodics deal provides a precedent for "litigate the fix" strategies in concentrated medtech market segments